Diagnostics
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Yet another company has launched to develop liquid biopsies. Founded and headed by Omid Farokhzad, formerly a professor at Brigham and Women’s Hospital, Seer is based in San Francisco.
QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus on genotypic drug resistance testing for those infected with tuberculosis.
With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
According to consultant firm Frost & Sullivan, artificial intelligence (AI) systems will be the next big players in both global healthcare and individual gene editing. By 2021, the firm predicts that AI will be responsible for 6.7 billion dollars in revenue.
The U.S. Food and Drug Administration (FDA) has issued an approval letter for the new features and intended uses of the Planmed Verity® CBCT scanner. Planmed is very pleased to bring these exciting improvements to the U.S. market.
Many recent college graduates with science degrees wonder, “What other careers are available outside of a laboratory or research environment?” Concurrently, a large amount of mid-career and late-career professionals consider pursuing non-traditional science roles.
INTEGRA’s VIAFLO 96 electronic multi-channel pipetting system is helping biotechnology company HCS Pharma to improve the reproducibility of high content screening using its patented BIOMIMESYS® 3D cell culture technology.
An expert in the application of artificial intelligence in precision medicine, Christophe Béesau’s appointment will allow Metafora to step up its efforts in oncology and immunology
Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease.
PRESS RELEASES